What We're Reading: Page 391
Industry reads hand-picked by our editors
Apr 08, 2015
-
Reuters
FDA accepts Novo's resubmission for insulin Tresiba
-
SF Business Journal
Next-gen, low-dose Gilead HIV drug heads to FDA
-
The Pink Sheet (gated)
Biosimilar costs could exceed brands' prices in Medicare Part D
-
In-Pharmatechnologist
Indian pharma and French regulators lock horns over med suspensions
Apr 07, 2015
Apr 06, 2015
-
Seeking Alpha
Alkermes antipsychotic shows promise in phase II
-
In-Pharmatechnologist
Sanofi R&D chief slams pharma's fixation with super specialty meds
-
Pharma Times
Pfizer, Bind Therapeutics extend Accurins alliance
Apr 02, 2015
-
Reuters
India to reportedly add TB, AIDS drugs to price cap list
-
Reuters
Merck, NewLink Ebola vaccines appear safe and effective
-
In-Pharmatechnologist
Peer review journal cheating scandal rages on
-
FierceBiotech
Sanofi strikes $120M drug design deal with Schrödinger
Apr 01, 2015
-
Wall Street Journal
US pharmacists' group urges members not to participate in executions
-
Bloomberg
Former Allergan CEO Pyott making off with $534M cash after stock sale
-
Statesman Journal
Oregon 'Right to Try' bill passes House committee
-
FiercePharma
Gilead chief Martin gets a 23% pay hike
-
Pharma Times
GW Pharma tests marijuana med in phase III epilepsy trial
Mar 31, 2015
-
Reuters
BioCryst wins US contract to continue Ebola drug development
-
Bloomberg
Quintiles and Quest join forces to form clinical trials mega-venture
-
StreetInsider
Merck, Syndax Pharma to collaborate on cancer trial using Keytruda
-
FierceBiotech
Fujifilm acquires pioneering stem cell firm Cellular Dynamics for $307M
Mar 30, 2015
-
Reuters
Sanofi may not be on pharma's M&A bandwagon
-
Bloomberg
Horizon strikes $1.1 billion deal for Hyperion and its orphan drugs
-
ProPublica
Medicare spent 15 times as much on hep C drugs last year
-
Bloomberg
Bucking DTC trend, Pfizer spent $1.4 billion on ads in 2014
-
FiercePharma
Baxter execs nab big bucks in midst of Baxalta spinoff
Previous
